BLCO Company Profile and Key Details
NYSE : BLCO
Bausch + Lomb
$16.70
0.04000076+0.24%
Open: 10:08 AM73.49
B+ESG ScoreESG Rating
Price Chart
Stock Price Today
Bausch + Lomb Corporation (BLCO) stock surged +0.24%, trading at $16.70 on NYSE, up from the previous close of $16.66. The stock opened at $16.74, fluctuating between $16.58 and $16.76 in the recent session.
Stock Snapshot
16.66
Prev. Close
5.95B
Market Cap
16.575
Day Low
25.69
P/E Ratio
0.65
EPS (TTM)
-0.56
Cash Flow per Share
16.74
Open
356.54M
Number of Shares
16.755
Day High
10.31%
Free Float in %
19.53
Book Value
17.29K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 16.99 | 16.99 | 16.38 | 16.66 | 355.95K |
| Jul 07, 2026 | 17.30 | 17.46 | 17.10 | 17.10 | 316.32K |
| Jul 06, 2026 | 17.18 | 17.21 | 16.99 | 17.11 | 346.83K |
| Jul 02, 2026 | 16.78 | 17.25 | 16.54 | 17.16 | 490.95K |
| Jul 01, 2026 | 16.67 | 16.99 | 16.55 | 16.55 | 464.17K |
| Jun 30, 2026 | 16.35 | 16.66 | 16.32 | 16.56 | 423.1K |
| Jun 29, 2026 | 16.45 | 16.66 | 16.24 | 16.63 | 264.6K |
| Jun 26, 2026 | 15.96 | 16.69 | 15.93 | 16.32 | 414.53K |
| Jun 25, 2026 | 15.64 | 16.03 | 15.64 | 15.91 | 332.76K |
| Jun 24, 2026 | 15.29 | 15.89 | 15.29 | 15.51 | 296.65K |
| Jun 23, 2026 | 14.86 | 15.30 | 14.86 | 15.24 | 418.15K |
| Jun 22, 2026 | 14.85 | 15.11 | 14.76 | 14.93 | 425.28K |
| Jun 18, 2026 | 14.88 | 15.00 | 14.82 | 14.87 | 334.17K |
| Jun 17, 2026 | 14.99 | 15.12 | 14.65 | 14.86 | 666.96K |
| Jun 16, 2026 | 15.10 | 15.21 | 14.95 | 14.99 | 396.07K |
| Jun 15, 2026 | 15.26 | 15.40 | 14.89 | 15.00 | 290.89K |
| Jun 12, 2026 | 15.40 | 15.44 | 15.04 | 15.08 | 276.31K |
| Jun 11, 2026 | 15.30 | 15.41 | 15.07 | 15.29 | 340.36K |
| Jun 10, 2026 | 15.49 | 15.69 | 15.20 | 15.26 | 258.97K |
| Jun 09, 2026 | 15.35 | 15.77 | 15.35 | 15.65 | 472.48K |
Contact Details
About Company
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Company Information
| Employees | 13500 |
| Beta | 0.57 |
| Sales or Revenue | $4.15B |
| 5Y Sales Change% | 0.13% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Stock Peers
WST
-2.4-0.67%
West Pharmaceutical Services, Inc.$353.68BDX-5.74-3.67%
Becton, Dickinson and Company$150.56TFX-3.19-2.39%
Teleflex Incorporated$130.35ATR-3.48-2.73%
AptarGroup, Inc.$124.21HAE-1.06-1.42%
Haemonetics Corporation$73.82WRBY-0.37-1.32%
Warby Parker Inc.$27.67BAX-0.88-3.85%
Baxter International Inc.$21.98STVN-0.27-1.38%
Stevanato Group S.p.A.$19.32AVTR-0.44-4.31%
Avantor, Inc.$9.76Company Overview
Bausch + Lomb Corporation (NYSE:BLCO) closed at $16.66 USD, losing -$0.44 (-2.57%) from the previous close of $17.10. The stock is currently mid-range between its 52-week high and low $13.09 and $18.91. With a market capitalization of about $5.94 billion, Bausch + Lomb Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 445.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Vaughan, ON, Bausch + Lomb Corporation operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Brenton L. Saunders, the company employs approximately 13,500 people and listed since May 06, 2022. Bausch + Lomb Corporation is a leading global eye health company.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 6.92%, SMA50 7.7%, SMA200 23.51%). The stock’s 14-day RSI is 68.84 (firm momentum), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.25% below its high and over 76.94% above its low. Average 10-day trading volume of 380.27 thousand shares is below the 3-month average of 436.62 thousand, indicating normal recent market interest.
Valuation Metrics
Bausch + Lomb Corporation trades at a P/E ratio of -26.84, slightly below the S&P 500 average, with a price-to-sales ratio of 1.14 and a price-to-book ratio of 0.93 suggesting the stock is closer to book value. The P/FCF stands at 1368.33, also above market averages.
Dividend & Fair Value
Bausch + Lomb Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.87. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Wall Street analysts project EPS growth of 39.78% annually over the next five years. The latest quarter delivered EPS of $0.08. The next quarter is forecast at $0.06. Next year's EPS is expected at -$4.37. Analyst sentiment is neutral. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 16 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $21.00 to $13.00. The high target offers 26.05% upside. The low target suggests -21.97% downside. The mean target is $17.20. This offers 3.24% upside. Bausch + Lomb Corporation earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by 33.33%. The prior quarter beat by -8.57%. Over the last six quarters, Apple has recorded several small beats. These include 4.17% in February 19, 2025.
Shareholding & Insider Activity
Bausch + Lomb Corporation has 356.54 million shares outstanding. The public float is 44.91 million shares, elevated short interest at 9.03% of float. This equals 4.06 million shares. The short ratio is 8.08 days. Institutional investors hold 94.57% of the float. Insiders own 88.06%. Bausch Health Companies Inc. holds 310.45 million shares, SAUNDERS BRENT L has 966.58 thousand shares and Eldessouky Sam has 403.13 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.
Financial & Profitability Overview
On valuation metrics, Bausch + Lomb trades at a P/E of -26.84, P/S of 1.14 and P/B of 0.93. The current ratio is 1.53 and quick ratio is 0.99. Operationally, the company’s inventory turnover is 2.35 and cash conversion cycle is 168.01 days. Debt-to-equity is 0.79, supported by a cash flow-to-debt ratio of 0.07.
Quarterly Financial Highlights
The company ended the quarter with $331.00M in cash and short-term investments, a total debt of $4.56B, and net debt of $4.23B. Total assets were $13.44B, with equity of $6.92B. Financials further reflected weakness, with operating cash flow of - $17.00M, free cash flow of - $198.00M, and capital expenditures of - $181.00M.
Price Forecast & Outlook
Our AI price prediction model suggests that Bausch + Lomb Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.63%, with price expected at $18.93 by July 22, 2026, within a range of $18.54 to $19.33 3-Month Outlook: Projected fall of -3.66%, reaching $16.05 by October 06, 2026, with a range of $15.32 to $16.69. 1-Year Outlook: Projected loss of -4.44%, with price at $15.92 by July 08, 2027, within a range of $15.21 to $16.66.
Key Takeaways
Bausch + Lomb Corporation (NYSE:BLCO) shares are flat 0.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bausch + Lomb Corporation trading at a premium to the broader market with a P/E of -26.84. Analyst sentiment is cautious, with the majority of ratings in In-Line territory and a mean price target of $18.99, suggesting 13.99% upside. Our AI forecast model points to short-term strength (13.63% over two weeks), a medium-term fall (-3.66% over three months), and a longer-term loss (-4.44% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Bausch + Lomb Corporation (BLCO) stock price?
Bausch + Lomb Corporation (NYSE: BLCO) stock price is $16.70 in the last trading session. During the trading session, BLCO stock reached the peak price of $16.76 while $16.58 was the lowest point it dropped to. The percentage change in BLCO stock occurred in the recent session was 0.24% while the dollar amount for the price change in BLCO stock was $0.04.
BLCO's industry and sector of operation?
The NYSE listed BLCO is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Bausch + Lomb Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BLCO?
Mr. Brenton L. Saunders J.D.
Executive Chairman
Mr. A. Robert D. Bailey
Executive Vice President & Chief Legal Officer
Mr. Andrew Stewart
Pres of Pharmaceuticals
Mr. Luc Bonnefoy
Pres of Surgical
Dr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Mr. Dennis Asharin
Executive Vice President, Head of Quality, Chief Global Manufacturing & Supply Chain Officer
Mr. John Ferris
Executive Vice President of Consumer
Mr. Jonathon L. Kellerman
Chief Compliance Officer
T.J. Crawford
Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D.
Chief Corporation Devel. & Digital Officer
Ms. Asli Gevgilili
Chief HR Officer
Mr. Frederick J. Munsch
Senior Vice President
Dr. Yehia Hashad M.D.
Executive Vice President of R&D and Chief Medical officer
Mr. Joseph C. Papa
Chief Executive Officer & Director
Mr. Joseph F. Gordon
Pres of Global Consumer, Surgical & Vision Care
Mr. Osama A. Eldessouky
Executive Vice President & Chief Financial Officer
Mr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Ms. Christina M. Ackermann
Executive Vice President, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals
Ms. Kelly Webber
Executive Vice President & Chief HR Officer
Luc Bonnefoy
Senior Vice President of Surgical
Executive Chairman
Mr. A. Robert D. Bailey
Executive Vice President & Chief Legal Officer
Mr. Andrew Stewart
Pres of Pharmaceuticals
Mr. Luc Bonnefoy
Pres of Surgical
Dr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Mr. Dennis Asharin
Executive Vice President, Head of Quality, Chief Global Manufacturing & Supply Chain Officer
Mr. John Ferris
Executive Vice President of Consumer
Mr. Jonathon L. Kellerman
Chief Compliance Officer
T.J. Crawford
Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D.
Chief Corporation Devel. & Digital Officer
Ms. Asli Gevgilili
Chief HR Officer
Mr. Frederick J. Munsch
Senior Vice President
Dr. Yehia Hashad M.D.
Executive Vice President of R&D and Chief Medical officer
Mr. Joseph C. Papa
Chief Executive Officer & Director
Mr. Joseph F. Gordon
Pres of Global Consumer, Surgical & Vision Care
Mr. Osama A. Eldessouky
Executive Vice President & Chief Financial Officer
Mr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Ms. Christina M. Ackermann
Executive Vice President, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals
Ms. Kelly Webber
Executive Vice President & Chief HR Officer
Luc Bonnefoy
Senior Vice President of Surgical
How BLCO did perform over past 52-week?
BLCO's closing price is 27.27% higher than its 52-week low of $13.09 where as its distance from 52-week high of $18.92 is -11.92%.
How many employees does BLCO have?
Number of BLCO employees currently stands at 13,500.
Link for BLCO official website?
Official Website of BLCO is: https://www.bausch.com
How do I contact BLCO?
BLCO could be contacted at phone 905 695 7700 and can also be accessed through its website. BLCO operates from 520 Applewood Crescent, Vaughan, ON L4K 4B4, Canada.
How many shares of BLCO are traded daily?
BLCO stock volume for the day was 17.29K shares. The average number of BLCO shares traded daily for last 3 months was 449.38K.
What is the market cap of BLCO currently?
The market value of BLCO currently stands at $5.95B with its latest stock price at $16.70 and 356.54M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep